Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors. The achievement grants Ginkgo with additional equity in Phytolon, and paves the way to explore further collaborations in the field of natural food colors.YOKNE'AM ILLIT, Israel and BOSTON, April 30 ...

Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON, April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Gink ...

Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $7.60, reflecting a +0.8% change from the previous day, underperforming the S&P 500 which gained 1.67% [1] - Over the past month, the company's shares increased by 5.9%, while the Medical sector and S&P 500 saw declines of 9.34% and 6.57% respectively [1] Upcoming Earnings - The upcoming earnings release is expected to show an EPS of -$1.23, a 61.56% increase compared to the same quarter last year [2] - Revenue is anticipated to be $41.26 million, indicating an 8.74% increase from the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at -$3.72 per share, representing a +64.09% change from the prior year, while revenue is expected to be $171.48 million, reflecting a -24.47% change [3] Analyst Estimates - Recent changes to analyst estimates indicate confidence in the company's business performance and profit potential [4] - The Zacks Rank system, which assesses estimate changes, currently ranks Ginkgo Bioworks Holdings, Inc. at 2 (Buy) [6] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [7] - Research indicates that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]

GINKGO BIOWORKS INVESTOR CONTACT: [email protected] GINKGO BIOWORKS MEDIA CONTACT: [email protected] AURA GENETICS MEDIA CONTACT: [email protected] Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "bel ...

Exclusive: As genetic testing company 23andMe seeks to sell the consumer data of millions of Americans as part of its bankruptcy proceedings, Senate HELP Committee Chairman Bill Cassidy is opening up a probe into the company to ensure that users' medical data and DNA do not fall into the wrong hands. In a pair of letters obtained by FOX Business, Cassidy, R-La., raised concerns with Treasury Secretary Scott Bessent and 23andMe executives over the risk that Chinese companies or other foreign adversaries may ...

Group 1 - Ginkgo Bioworks Holdings, Inc. (DNA) has experienced a significant decline of 28.8% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for DNA is currently at 20.73, suggesting that the heavy selling pressure may be exhausting itself, which could lead to a reversal towards the previous equilibrium of supply and demand [5] - There is strong consensus among Wall Street analysts that DNA will report better earnings than previously predicted, with the consensus EPS estimate increasing by 37.9% over the last 30 days [7] Group 2 - DNA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

According to data from online traffic analysis company Similarweb, on March 24, the day of the bankruptcy announcement, 23andMe received 1.5 million visits to its website, a 526% increase from one day prior. According to Similarweb, 376,000 visits were made to help pages specifically related to deleting data, and 30,000 were made to the customer care page for account closure. The next day, that figure rose to 1.7 million visits, and rraffic to the delete data help page about 480,000. Margaret Hu, professor ...

24/7 Market News- Kraig Labs Makes History: World Record DNA Insertion Unlocks Massive PotentialMarch 27, 2025 10:31 AM EDT | Source: 24/7 Market NewsDenver, Colorado--(Newsfile Corp. - March 27, 2025) -  247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Kraig Biocraft Laboratories' (OTCQB: KBLB) ("Kraig Labs") groundbreaking achievement-successfully inserting the largest functional DNA construct e ...

Core Points - 23andMe has filed for Chapter 11 bankruptcy protection, leading to concerns about the future of customer genetic data [4][6] - The company's co-founder and CEO, Anne Wojcicki, has resigned and plans to bid on the company during the bankruptcy sale process [5] - Privacy experts are advising users to consider deleting their data due to potential risks from new ownership and hackers [3][7] Company Situation - The bankruptcy filing aims to facilitate the sale of substantially all assets and reduce operational costs by rejecting certain lease contracts [6] - 23andMe intends to continue operations during the bankruptcy process [6] - The company has faced previous data breaches, including a 2023 incident that exposed the genetic data of nearly 7 million customers [8] Data Privacy Concerns - Experts highlight the sensitivity and value of genetic data, emphasizing that it is unique to each individual [9][10] - 23andMe claims it does not share data with health insurance companies or employers without user consent, but there are concerns about how data can still be used for targeted advertising [10][11] - California Attorney General has issued alerts regarding users' rights to delete their data amid the company's financial distress [12] User Data Management - Users can delete their data by accessing account settings and following specific steps to confirm deletion [13] - Users can also request the destruction of their saliva samples and withdraw consent for third-party research [14]

DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company’s more than 15 million customers.The former Silicon Valley darling sought Chapter 11 protection on Sunday after struggling with weak demand for its ancestry testing kits that once featured in Oprah Winfrey’s annual list of favorite things, and following a 2023 data breach that damaged its reputation. 7 DNA testing pioneer 23andMe, one of Silicon Valley’s most recognized biotech st ...